Enhanced differentiation of human embryonic stem cells (HESCs), induced by genetic modification could potentially generate a vast number of diverse cell types. Such genetic modifications have frequently been achieved by over-expression of individual regulatory proteins. However, careful evaluation of the expression levels is critical, since this might have important implications for the differentiation potential of HESCs. To date, attempts to promote osteogenesis by means of gene transfer into HESCs using the early bone ''master'' transcription factor osterix (Osx) have not been reported. In this study, we attained HESC subpopulations expressing two significantly different levels of Osx, following lentiviral gene transfer. Both subpopulations exhibited spontaneous differentiation and reduced expression of markers characteristic of the pluripotent phenotype, such as SSEA3, Tra1-60, and Nanog, In order to promote bone differentiation, the cells were treated with ascorbic acid, b-glycerophosphate and dexamethasone. The high level of Osx, compared to endogenous levels found in primary human osteoblasts, did not enhance osteogenic differentiation, and did not up-regulate collagen I expression. We show that the high Osx levels instead induced the commitment towards the hematopoietic-endothelial lineage-by up-regulating the expression of CD34 and Gata1. However, low levels of Osx up-regulated collagen I, bone sialoprotein and osteocalcin. Conversely, forced high level expression of the homeobox transcription factor HoxB4, a known regulator for early hematopoiesis, promoted osteogenesis in HESCs, while low levels of HoxB4 lead to hematopoietic gene expression.
Bone marrow (BM) together with the lining of the internal bone surface, endosteum, is the only site for hematopoiesis during adult life, but the molecular mechanisms regulating the hematopoietic microenvironment within BM are largely unknown. Multi-potent hematopoietic stem cells (HSCs) give rise to lineage restricted cells (Gong, 1978; Kondo et al., 2003) , and recent investigations have demonstrated that early hematopoietic progenitors localize to the subendosteal areas, adjacent to the bone cortex . Furthermore, reciprocal functional effects between osteogenesis and blood cell differentiation have been reported Calvi, 2006; Mankani et al., 2007; Zhu et al., 2007) .
Osteoblasts, bone producing cells, originate from multi-potent mesenchymal stem cells (Pittenger et al., 1999) , and require the expression of osterix (Osx) (Nakashima et al., 2002; Yoshida et al., 2002) , which is currently recognized as the only osteoblast-specific transcription factor. Osx is a recently identified zinc finger-containing transcription factor encoded by the Sp7 gene, which regulates gene expression in committed osteoblastic precursor cells, acting downstream of Runx2 (Nakashima et al., 2002) . Little is know about the function of Osx and its downstream target genes. Further differentiation regulated by Osx requires the activation of many pathways, such as bone morphogenetic protein signaling pathway (Yagi et al., 2003) , as well as several other pathways (Bennett et al., 2005; . Osx also interacts with SWI/SNF complexes involved in chromatin remodeling (Hatta et al., 2006) . A few studies describing the ectopic expression of Osx using mouse embryonic stem cells (mESCs) have been reported (Tai et al., 2004) , and more recently, also by using human embryonic stem cells (HESCs) (Tai et al., 2005) and fibroblasts (Kim et al., 2006) . The forced expression of Osx stimulated osteocalcin (Ocn) gene expression, a late marker for mature osteoblasts, in non-osseous myoblasts (Nakashima et al., 2002) . However, another study reported that Osx ectopic expression in fibroblasts suppressed the expression of collagen type I, and no ''typical'' bone-like nodule formation was observed. Osx enhanced the proliferation of fibroblasts and increased the expression of osteopontin during osteogenic differentiation, although it was found to be not sufficient to convert non-osseous cells into osteoblastic cells (Kim et al., 2006) .
To date, no data are presented about Osx potential interactions with exclusively blood-related factors. A developmentally intriguing transcription factor known to improve hematopoietic maturation from HESCs, human homeobox B4 (HoxB4) is expressed in self-renewing definitive HSCs, and is down-regulated upon maturation towards committed blood cells (Sauvageau et al., 1995) . Similarly to Osx it is dependent on confounding factors (Krosl et al., 1998) and can strongly affect the hematopoietic phenotype and function.
In the present study, we sought to investigate if Osx and HoxB4, two transcription factors involved in the early development of two distinct lineages, have an inductive effect on differentiating HESCs, looking at the expected osteogenesis and hematopoiesis. We demonstrate that in order to achieve enhanced differentiation towards a desired lineage, it is important to direct the embryonic stem cell differentiation with correct levels of transcription factors. Additionally, our data also highlights close relationship between early blood and bone development.
Materials and Methods
Cell culture HESC line, H9 (from WiCell Research Institute, Madison, WI under WiCell Agreement #02-W183) with a normal karyotype was cultured as published (Karner et al., 2007) . Human osteoblasts (hOBL) (Cambrex Bio Science Walkersville, Inc., Walkersville, MD), the human osteosarcoma cell line Saos-2 (HTB-85, ATCC, Manassas, VA) and the epithelial line HEK293-EBNA were maintained in Dulbecco's Modified Eagle's Medium (DMEM, high glucose) containing glutamine and 10% fetal bovine serum (FBS) (all from Invitrogen AB, Stockholm, Sweden). The K562 cell line (LGC Promochem/ATCC) was cultured in RPMI-1640 (Invitrogen) supplemented with 10% FBS.
Plasmid construction
Three lentiviral vectors were constructed for this study; the main vector expressing an Osx-enhanced green fluorescence (EGFP) fusion gene, an EGFP expressing control vector, and a control vector expressing an EGFP-enhanced 2A linker (E2a)-HoxB4 fusion gene.
Human Osx cDNA was ligated between the EcoRI and AgeI sites of pEGFP-N1 vector (Clontech, Palo Alto, CA). The Osx cDNA, originally cloned into the TOPO vector (Gao et al., 2004) was amplified with a vector-specific primer in the forward direction and with the primer 5 0 -CCACACCGGTCCGATCTCCAGCAAGTT-GC-3 0 in the reverse direction. The sequence was subsequently cleaved with EcoRI and AgeI. The reverse primer contained an AgeI site in frame with Osx and the pEGFP-N1 coding sequences. The STOP codon was replaced by a Gly codon. Therefore, the construct encoded the entire Osx until its last amino acid (Ileu), followed by the necessary connecting peptide GPVAT and by EGFP. The EcoRI site at the 5 0 end of the Osx sequence came from the original TOPO cloning vector, and was followed by an additional six vector nucleotides (GCCCTT) before reaching nucleotide number 69 (Accession AF477981) of the Osx cDNA sequence.
In order to create the lentiviral vector, the Osx-EGFP fusion sequence was cleaved from the pEGFP-N1-Osx construct with EcoRI and NotI, and ligated into the same sites of the Gateway plasmid pENTR4 (Invitrogen). The construct was then transferred into the lentiviral backbone pLenti6/UbC/V5-DEST (Invitrogen) using the Gateway 1 LR recombination enzymes (Invitrogen). This construct was named pLenti6-Osx-EGFP.
The EGFP-control plasmid was constructed by subcloning the EGFP gene from pEGFP-N1 into the Gateway 1 plasmid pENTR4 using EcoRI and NotI. From there the EGFP gene was recombined with the lentiviral backbone pLenti6/UbC/V5-DEST using the Gateway 1 LR reaction to produce the lentiviral expression plasmid pLenti6-EGFP.
Human genomic HoxB4 was cloned from extracted donor buffy coat DNA using the following primers; upper primer 5 0 -GGATC-CATAGGAGGGCTTTCGGAAACA-3 0 , with an addition of a BamHI site (bold), lower primer 5 0 -GGGGGAGGGCAGATAG-ATTT-3 0 . The gene was cloned into the pCR Blunt II TOPO vector (Invitrogen), and subcloned into pEGFP-C3 (Clontech) to produce the pEGFP-HoxB4 fusion plasmid. The E2A sequence from pSTA1/33 (Donnelly et al., 2001) was inserted between EGFP and HoxB4 creating the EGFP-E2A-HoxB4 fusion fragment that was subcloned into the Gateway 1 pENTR4 plasmid. To obtain the final lentiviral transfer vector, the EGFP-E2a-HoxB4 fusion gene in pENTR4 was recombined with pLenti6/UbC/V5-DEST using the Gateway 1 LR reaction according to manufactures instructions (Invitrogen), and named pLenti6-EGFP-HoxB4.
The DNA structure in the individual steps was tested by restriction enzyme analysis and the final constructs were verified by sequencing.
Production and concentration of lentiviral vectors
Virus was produced by transient co-transfection of three plasmids into 293FT cells (Invitrogen). Briefly, 400,000 cells were transfected using the FuGENE6 Transfection Reagent (Roche, Boehringer Mannheim, Germany) according to manufacturer's instructions with a total of 6 mg of plasmid DNA: 1 mg of the envelope plasmid pMDG harboring the gene encoding vesicular stomatitis virus glycoprotein (VSV-G), 2 mg of the pCMVDR8.91 expressing Gag and Pol (both plasmids kindly provided by Dr. D Trono, Department of Genetics and Microbiology, University of Geneva, Geneva, Switzerland), and 3 mg of our transfer vector constructs. The medium was replaced 20-24 h after transfection with KnockOut-Dulbecco's Modified Eagle's Medium (KO-DMEM) supplemented with 17% KnockOut-Serum Replacement (KO-SR) (Invitrogen). The medium containing the viral particles was collected 48 and 72 h after transfection and filtered through 0.45 mm Millex-GP syringe-top filter (Millipore Corporation, Bedford, MA). Viral titers (TU/ml) were determined by transduction of Hela cells (ATCC) with serial dilutions of the viral supernatant and flow cytometric analysis of the percentage of EGFP-expressing cells. The viral particles were concentrated by centrifugation at 50,000g for 2 h in a Beckman ultracentrifuge, resuspended in HESC-culture medium and frozen at À808C until further use.
To verify the functional expression of our transgenes, the Saos-2 cells were transduced with the viral supernatant and analyzed for EGFP expression using flow cytometry.
For transduction with lentiviral vectors, low passage (p35-50) H9 HESCs were plated onto 24-well-plates (Corning, NY) using blasticidin-resistant feeder cells (100,000 cells/well), which were prepared by transducing the human fibroblasts with pLenti6/UbC/ V5-GW-lacZ control vector (Invitrogen) followed by chemical selection with 5 mg/ml blasticidin (Invitrogen). Four days after splitting, HESC colonies covered 30-50% of the surface, and the lentiviral particles containing medium with 5 mg/ml polybrene (Sigma-Aldrich, St. Louis, MO) was added to the cells. Due to a more randomized outgrowth of transduced HESCs the independent experiments resulted in two subpopulations expressing high and low levels of our transgenes.
Flow cytometric analysis
The cells were washed with phosphate-buffered saline (PBS) and dissociated using TrypLE Express (Invitrogen). Subsequently the cells were incubated for 20 min at 48C in DMEM containing 5% FBS with the following fluorescent labeled monoclonal antibodies: CD34-Allophycocyanine (APC), CD31-Phycoerythrin (PE) and their corresponding isotype controls (BD Biosciences, San Jose, CA). For detection of pluripotency markers stage specific embryonic antigen-3 (SSEA3), and tumor rejection antigen-1-60 (Tra1-60) (kindly provided by Dr Mark Jones from the lab of Professor Peter Andrews, The University of Sheffield, Sheffield, UK), the cells were incubated with the primary antibody at 1:10 dilution followed by a secondary Cy5-conjugated anti-rat IgM (for SSEA3) or anti-mouse IgG (for Tra1-60) antibody (Chemicon, Temecula, CA) at 1:200 dilution. All antibodies were optimized in terms of their concentration, and the staining was performed on ice to prevent quenching of the signals. Finally the cells were washed in PBS, centrifuged at 300g for 5 min, and resuspended in DMEM containing 5% FBS. Non-viable cells were identified by their ability to incorporate propidium iodide (Sigma-Aldrich). Flow cytometric analysis was performed on a FACSCalibur (BD Biosciences). Acquisition and analysis was performed using BD CellQuest TM Pro (BD Biosciences) and FlowJo (Tree Star, Ashland, OR) software.
Isolation of CD34R cells from peripheral blood
Peripheral blood mononuclear cells were isolated from buffy coats of healthy blood bank donors by gradient centrifugation, using Lymphoprep (Nyegaard, Oslo, Norway). CD34þ cells were isolated with Midi columns using MACS CD34 Microbeads from Miltenyi Biotec (Bergisch Gladbach, Germany) following the manufacturer's instructions. After the second purification we obtained 200,000 CD34þ cells with 95% purity from a total of 300,000,000 white blood cells.
Endothelial cell preparation
Primary umbilical cord derived cells obtained from three donors were kindly provided by Dr N. Gautam (Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden). Purity analysis was performed by flow cytometry using directly labeled CD31-PE and CD34-APC antibodies (both from BD Biosciences). Passage 0 cells were >92% double positive for CD31 and CD34.
Differentiation assay
The experiments were repeated on three separate occasions. To initiate cell differentiation, the HESCs were removed from a culture dish by incubation with collagenase NB5 (1 mg/ml) (Serva Electrophoresis GmbH, Heidelberg, Germany) solution in KO-DMEM, and mechanically scraping from the culture plate. Cells were seeded onto 12-well-plates coated with 0.1% gelatine. Osteogenic differentiation was performed as published (Karner et al., 2007) . To analyze the effect of cellular density, the cultures were split at a 1:2 ratio after 7 days. hOBLs were grown in the basal culture medium (DMEM, 1% GlutaMAX, 10% FBS) for 15 days with (hOBL d15-og) and without (hOBL d15-ctr) supplementation of 10 mM b-glycerophosphate, 50 mg/ml ascorbic acid phosphate and 1 mM dexamethasone (all from Sigma-Aldrich).
Quantitative real-time RT-PCR (Q-PCR)
Total RNA was extracted from undifferentiated and differentiated H9 cell line and hOBLs, modified and unmodified Hela cells, purified CD34þ cells, and human umbilical cord CD31þ/CD34þ endothelial cells using RNeasy Kit (Qiagen, VWR International AB, Stockholm, Sweden) as described by the manufacturer.
First-strand cDNA was reverse transcribed from Dnase-treated 2 mg of total RNA using 100 units SuperScript TM III reverse transcriptase, 200 ng random primers and RNase inhibitor (all from Invitrogen). cDNA from human mesenchymal stem cells (hMSCs) cultured as described (Le Blanc et al., 2003; Gotherstrom et al., 2005; Ringden et al., 2006) was kindly provided by Dr M. Uzunel (Department of Clinical Immunology, Karolinska University Hospital Huddinge, Stockholm, Sweden). One sample of cDNA from human primary osteoblasts (hOBL primary) was kindly provided by Dr T. Lind (Department of Medical and Physiological Chemistry, Uppsala University, The Biomedical Center, Uppsala, Sweden).
Q-PCR was carried out using Applied Biosystems 7500 Fast Real-Time PCR system with ABI PRISM. Reactions were performed using 40 ng cDNA, TaqMan Universal PCR Mastermix and primers/probes for hydroxymethylbilane synthase (HMBS) (1Â Assays-on-Demand, Hs00609297_m1), human Osx (Hs00541729_m1), human homeobox transcription factor Nanog (Hs02387400_g1), human collagen type I A1 (collagen I) (Hs00164004_m1), human HoxB4 (Hs00256884_m1), human Gata1 (Hs00231112_m1), and EGFP (custom made TaqMan 1 assay against EGFP: forward GAGCGCACCATCTTCTTCAAG, reverse: TGTCGCCCTCGAACTTCAC) (all from Applied Biosystems, Foster City, CA). The reactions were run at 508C for 2 min, 10 min at 958C, followed by 958C 15 sec, 608C 40 sec, and cycling 40 times in the last two steps.
Amplification of human bone sialoprotein (Bsp) and Ocn was carried out using the SYBR 1 GREEN Master Mix (Applied Biosystems) in the reactions in combination with 2.5 ml water, 40 ng cDNA, and the specific primers (0.2 mM). The primer sequences were used as published previously (Karner et al., 2007) .
The comparative cycle threshold (C t ) (Meijerink et al., 2001; Chang et al., 2002) method was used to analyze data.
SDS-PAGE and Western blot
Osx-EGFP expressing Hela, unmodified Hela as a control for Osx-EGFP, and Saos-2 cells were lysed using the TRIzol reagent (Invitrogen) and protein extracts were quantified using the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Seven micrograms of each sample in Laemmli buffer containing bmercaptoethanol was electrophoresed on a SDS-PAGE 4-15% mini-gel (Bio-Rad). Proteins were electroblotted onto nitrocellulose membranes (Hybond-ECL, GE Healthcare, Buckinghamshire, UK) and blocked in 3% milk solution in Trisbuffered saline (TBS) and 0.1% Tween-20. The membranes were probed with human anti-Osx (1:200, from B. Ganss, Toronto University, Canada), anti-Bsp (1:2,000, Chemicon), anti-collagen I (1:200, Santa Cruz Biotechnology, Inc., SDS Biosciences, Falkenberg, Sweden), anti-actin (1:20,000, Sigma-Aldrich) antibodies diluted in blocking solution, followed by a corresponding horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000, DAKO, Glostrup, Denmark). Proteins were detected with ECL Plus Western Blotting Detection System (GE Healthcare).
For the detection of HoxB4 in modified and unmodified Hela cells, the total protein was extracted from unmodified K562 and Hela cells, and electrophoresed on a 10% pre-cast gel (Bio-Rad Laboratories). Gels were blotted onto PVDF membranes (Bio-Rad), which were probed with rat anti-HoxB4 hybridoma supernatant (Developmental Studies Hybridoma Bank, IA) overnight followed by secondary anti-rat IgG antibody conjugated to HRP (DAKO) at 1:2,000. As a loading control, a primary anti-actin antibody (Sigma-Aldrich) at 1:500,000 followed by secondary anti-mouse HRP (DAKO) at 1:2,000 was used. Bound antibodies were detected using SuperSignal West Pico Chemoluminescent Substrate (Pierce, Rockford, IL).
Immunocytochemical analysis
The degree of differentiation was inspected by examining the expression of Nanog (ab21603, Abcam, www.abcam.com), Tra1-60, SSEA1 (both antibodies provided by Dr Mark Jones from the lab of Professor Peter Andrews, The University of Sheffield, Sheffield, UK). The HESC cultures were washed with PBS, fixed in 4% paraformaldehyde, after that rinsed again with PBS, and blocked with 2% FBS, 0.1% BSA for 2 h at room temperature. For Nanog staining 0.1% Triton-X was added to the solution. Thereafter the cells were incubated at 48C overnight with the primary antibody Nanog (1:200), or SSEA1 (1:200) in PBS containing 0.1% BSA. 0.1% Triton-X was added to the Nanog antibody solution. The samples were washed four times with PBS, and incubated with the secondary antibody (1:200, rhodamine-conjugated goat anti-rabbit IgG, Chemicon) diluted in 0.1% BSA (0.1% Triton-X was added for Nanog samples) in PBS 1 h at room temperature in the dark. For the nuclear staining the samples were incubated with 5 mg/ml DAPI (Invitrogen) for 10 min in the dark, and thereafter washed with PBS.
EdU proliferation assay
The effect of the over-expressed genes on the proliferation of HESCs was analyzed using Click-iT TM EdU Alexa Fluor 1 647 flow cytometry assay (Invitrogen) following the manufacturers instructions. In brief, cells were incubated for 15 h with the thymidine analogue EdU (5-ethynyl-2 0 -deoxyuridine), and after treated with TrypLE. The feeder cells were removed by allowing them to attach for 1 h onto the cell culture dish. The HESCs were then fixed, permeabilized, stained with a fluorescent dye azide and detected by flow cytometry.
Mineralization assay
As an indicator of mineralization within cultures from days 7, 14, 21, and 25, calcium deposition was analyzed by Alizarin Red S staining as described previously (Karner et al., 2007) .
Statistical analysis
Transductions were performed at least three times, and differentiation experiments were set up on at least three instances. Samples for endogenous controls were included from three separate occasions, unless otherwise stated. The data is expressed as mean AE standard error of the mean (SEM), and was analyzed using unpaired Student's t-test. P values <0.05 were considered statistically significant.
Results

Generation of lentiviral based expression systems
Osx is primarily known to be essential for osteoblast differentiation (Nakashima et al., 2002) . In this study a commercially available lentiviral vector pLenti6/UbC/V5-DEST was used to ectopically express Osx in the HESC line H9. This type of vector facilitates chemical selection by blasticidin, and has previously been successfully used in the genetic modification of HESCs (Gropp et al., 2003; Ma et al., 2003; Suter et al., 2006) . To elucidate the effect of Osx on undifferentiated HESCs, we included into the study a hematopoietic transcription factor, HoxB4, which has been previously reported to not induce HESC differentiation when expressed ectopically (Bowles et al., 2006; Unger et al., 2008) . Furthermore, to reduce the potential of the HESCs to differentiate, we used the standard HESC medium for resuspension of viral particles after concentration and during transduction.
Three lentiviral constructs were prepared; EGFP, Osx-EGFP fusion gene and EGFP-HoxB4 fusion gene under the control of the human Ubiquitin C promoter (Fig. 1A) . The E2a sequence was inserted between EGFP and HoxB4 creating an EGFP-HoxB4 fusion gene, in which both proteins will be separated after translation. Viral functionality was determined by transduction of Hela cells and by analysis of synthesized proteins (Fig. 1B) . Saos-2 cells were included as endogenous controls for Osx expression and a 47 kDa band was detected by Western blot. In the Osx-EGFP transduced Hela cells, a 73 kDa protein was identified as containing the addition of 26 kDa EGFP protein. As an endogenous HoxB4 control the human myelogenous leukemia K562 cells were used to evaluate protein size and expression level (Bowles et al., 2006) . Strong bands for endogenous HoxB4 (30 kDa) were observed, and the size of HoxB4 protein in EGFP-HoxB4 transduced cells was accurate considering the separation by the E2a linker.
Q-PCR revealed that ectopic expression of Osx in transduced Hela cells yielded $7-fold higher levels of Osx when compared to Saos-2, and $18.6-fold higher expression compared to primary human osteoblasts (Fig. 1C) .
To assess promoter activity, we used the EGFP co-expression system and analyzed the Osx-EGFP protein expression in osteoblast-like Saos-2 cells (Fig. 1D) by flow cytometry. After one week blasticidin selection, EGFP protein was found in 97.5% (AE0.1 SEM) of cells transduced with the pLenti6-EGFP construct, and in 76.4% (AE0.44 SEM) of cells transduced with the pLenti6-OSX-EGFP construct.
Since little is known about Osx expression in other cell types, we evaluated the endogenous Osx levels in different related cell types, and the undifferentiated H9 HESC line was used to calibrate the values. In hMSCs, Osx was found to be 4.6-fold higher expressed, whereas in commercially available hOBLs a 10.2-fold higher expression was detected. These cells had been previously grown for 15 days in osteogenic differentiation medium (Fig. 1E ). HoxB4 expression levels were calibrated to the levels in K562 cell line which naturally expresses HoxB4 (Bowles et al., 2006) . We found that forced HoxB4 expression in Hela cells resulted in 1.7-fold higher levels of expression. Furthermore, we confirmed that the induced HoxB4 levels in Hela were above the naturally expressed levels found in other cell types, such as CD34þ peripheral blood cells, endothelial cells and hMSCs amongst others.
To determine whether pluripotent HESCs could be transduced with lentiviral vectors, the H9 line cultured on human fibroblasts was infected with our constructs. Transduction of HESCs with 100-fold concentrated virus resulted in the expression of the transgene by $35% of the cells, as detected by flow cytometry one week after transduction (data not shown). Analysis of the mRNA levels (in 100% selected cells compared to untransduced control cells) using Q-PCR revealed that transduced HESCs generated two subpopulations for both genes, which produced high and low levels of our transcription factors, and which were further named as H9-Osx-EGFP(high) (1,742 AE 278 SEM fold higher expression compared to H9-EGFP), H9-Osx-EGFP(low) (85.8 AE 23.9 SEM), H9-EGFP-HoxB4(high) (347.9 AE 80.5 SEM) and H9-EGFP-HoxB4(low) (5.4 AE 3.3 SEM). The levels of both Osx high and low ( P ¼ 0.0012), and HoxB4 high and low ( P ¼ 0.0005) were significantly different. The EGFP expression from the fusion genes correlated as expected with the expression of the gene-of-interest (Fig. 1F) .
Transgene expression during prolonged cultivation is associated with the partial loss of pluripotency Transgene expression was detected by the co-expression of EGFP ( Fig. 2A) and it did not have any apparent effect on HESC morphology. To determine whether the transduced HESCs retained their pluripotent potential, we performed immunocytochemical staining using markers linked to pluripotency. Undifferentiated cells expressed Nanog (Mitsui et al., 2003; Humphrey et al., 2004) and Tra1-60 but did not express SSEA1, a marker characteristic to the differentiated phenotype (Fig. 2B) . Furthermore, antibodies against SSEA3, detected a positive signal in 76.35% (AE8.2 SEM) of unmodified H9 alive cells, and in 61.1% (AE9.9 SEM) of H9-EGFP cells. However, the SSEA3 levels were decreased in H9-Osx-EGFP(high) cells (20.3% AE 8.1 SEM, P ¼ 0.06 when compared to H9-EGFP cells) and H9-Osx-EGFP(low) cells The pLenti6/UbC/V5-DEST was used to construct three vectors which contained the EGFP. Osterix (Osx) was directly fused to EGFP (Osx-EGFP), while the vector expressing HoxB4 has an inserted enhanced 2A linker (E2a), which allowed for the separation of HoxB4 and EGFP after translation (EGFP-HoxB4). All vectors are driven by the human ubiquitin promoter C. B: Western blot analysis was performed on whole cell extracts from unmodified Hela and transduced Hela cells. Saos-2 and K562 cells were used as positive controls for Osx and HoxB4 detection, respectively. C: Q-PCR analysis of the forced expression levels of Osx in Hela cells revealed a $7-fold higher expression levels compared to Saos-2, and an $18.6-fold higher levels compared to human primary osteoblasts (hOBL primary). D: Analysis of promoter activity by detecting the expression of Osx-EGFP fusion protein by flow cytometry in modified Saos-2 after one week of chemical selection. E: Endogenous Osx levels (upper part) calibrated to undifferentiated H9 cells. Increased levels of Osx were observed in primary human mesenchymal stem cells (hMSC) ($4.5-fold), and commercially available human osteoblasts that were grown 15 days in osteogenic conditions (hOBL d15-og) ($10.2-fold). Endogenous HoxB4 levels (lower part) were calibrated to K562 cells. Forced expression of HoxB4 in Hela was above the naturally occurring levels found in other cell types. F: Transduction of HESCs. Analysis of mRNA levels revealed that transduced HESCs generated two significantly different subpopulations for both Osx and HoxB4, which produced high and low levels of the transcription factors, and which were further named as H9-Osx-EGFP(high), H9-Osx-EGFP(low), H9-EGFP-HoxB4(high) and H9-EGFP-HoxB4(low). The EGFP expression correlated with the expression of the gene-of-interest.
(23.0% AE 6.0 SEM, P ¼ 0.029), as well as in H9-EGFP-HoxB4(high) (29.5% AE 2.7 SEM, P ¼ 0.036), and in H9-EGFP-HoxB4(low) (27.2% AE 4.4 SEM, P ¼ 0.08) (Fig. 2C) . Another surface-antigen, Tra1-60, was examined by flow cytometry. We found 89.5% (AE3.1 SEM) of unmodified H9 cells, and 76.2% (AE1.2 SEM) of H9-EGFP expressed Tra1-60. Osx and HoxB4 modified cultures displayed significantly lower expression of Tra1-60 on the cell surface when compared to . The colonies showed well-defined borders. Scale bar: 100 mm. B: Immunocytochemical staining with antibodies against Nanog, Tra1-60 and SSEA1. Nanog expression was observed within nuclei, scale bar 100 mm. Tra1-60 and SSEA1 signal was localized cellularly, scale bar 500 mm. C: Flow cytometry showed a reduced positive signal with antibodies against SSEA3 and Tra1-60 in cells which had been transduced with the Osx expressing vector. D: EdU incorporation after 15 h demonstrated the amount of proliferating cells in that time. E: Q-PCR analysis of Nanog expression at day 0 and after 7 days of culture in differentiation medium with b-glycerophosphate, ascorbic acid phosphate and dexamethasone. F: Transgene expression during differentiation. The cells were cultured in the differentiation medium for 14 days. Q-PCR analysis revealed that the expression of both transgenes increased throughout the differentiation period. Transgene (high) levels were significantly different from transgene (low) levels. Endogenous Osx and HoxB4 expression levels during the differentiation were analyzed in H9-EGFP cells.
the H9-EGFP cells. A positive signal was detected in 50.6% (AE8.2 SEM, P ¼ 0.008) H9-Osx-EGFP(high) cells, in 54.2% (AE6.2 SEM, P ¼ 0.009) H9-Osx-EGFP(low) cells, in 57.9% (AE7.8 SEM, P ¼ 0.04) H9-EGFP-HoxB4(high) cells and in 55.9% (AE10.8 SEM, P ¼ 0.04) H9-EGFP-HoxB4(low) cells (Fig. 2C) .
These results suggested that the transduced undifferentiated cells potentially possessed a reduced capacity of self-renewal during prolonged cultivation in vitro, although this was not significant amongst all tested markers. The proliferative status of modified cells, as assessed by analyzing the EdU incorporation after 15 h revealed a positive signal in 85.8% (AE1.1 SEM) H9-EGFP cells, in 83.3% (AE1.4 SEM) H9-Osx-EGFP cells, and in 87.8% (AE0.8 SEM) H9-EGFP-HoxB4 cells (Fig. 2D) . Based on these findings, we concluded that transgene expression did not exhibit a significant effect on the proliferation.
Moreover, we observed a decrease in the expression of Nanog in Osx-and HoxB4-modified cells. Nanog expression was significantly lowered to 56.2% (AE11.8 SEM) in H9-Osx-EGFP(high) samples ( P ¼ 0.037). A tendency of decreased Nanog expression was detected in H9-Osx-EGFP(low) (55.3% AE 223.0 SEM), H9-EGFP-HoxB4(high) (72.4% AE 37.7 SEM) and H9-EGFP-HoxB4(low) (92.5% AE 16.7 SEM) cells, however these changes were not significant. EGFP-transduced H9 cells were considered as 100% and the results are presented as a percentage of the expression of H9-EGFP (Fig. 2E ).
Transgene expression during differentiation is up-regulated
In addition, we confirmed that Nanog expression was down-regulated after culturing the cells 1 week in differentiation medium supplemented with b-glycerophosphate, ascorbic acid phosphate and dexamethasone, indicating that the cells were losing their pluripotency and undergoing differentiation (Fig. 2E) . The down-regulation, however, was not significant in high Osx expressing cells where at day 7 26.7% (AE19 SEM) cells were still Nanog positive. To examine the ubiquitin promoter driven transgene expression during differentiation, we cultured the cells for 2 weeks in the same differentiation medium. The Q-PCR analysis revealed transgene expression was increased throughout the differentiation period in vitro. Analysis of three time-points revealed a significantly higher expression in H9-Osx-EGFP(high) (d0: 1644 AE 186 SEM, d7: 1976 AE 317 SEM, d14: 3419 AE 161 SEM) and H9-EGFP-HoxB4(high) cells (d0: 196 AE 45 SEM, d7: 340 AE 95 SEM, d14: 1062 AE 650 SEM) when compared to H9-Osx-EGFP(low) (d0: 225 AE 0 SEM, d7: 324 AE 59 SEM, d14: 469.5 AE 115.6 SEM) and H9-EGFPHoxB4(low) (d0: 29.7 AE 18 SEM, d7: 18 AE 6 SEM, d14: 49 AE 7 SEM) (Fig. 2F) . Endogenous OSX levels in the control H9-EGFP cells increased slightly at day 7 (14.1 AE 8.1 SEM), and raised levels of endogenous HoxB4 were observed at day 14 (12 AE 4.5 SEM) albeit the endogenous expression levels were negligible compared to induced levels.
Low ectopic Osx expression enhances differentiation towards the osteogenic lineage
The HESCs over-expressing Osx were allowed to differentiate 25 days within the media supplemented with known osteoblastic inducers, b-glycerophosphate, ascorbic acid phosphate and dexamethasone. First, we noticed that after 1 week in culture the Osx expressing cells exhibited morphology similar to endothelial-like cells. HoxB4, which is a transcription factor for early hemato-endothelial lineage (for review see Klump et al., 2005 ) exhibited a similar phenotype (Fig. 3A) .
Marker genes associated with extracellular matrix formation, such as collagen I, and late osteoblastic phenotype, such as Bsp and Ocn, were chosen to detect whether Osx could enhance osteogenesis. Total RNA was isolated from cells grown for 7 and 14 days in the differentiation medium, and subjected to Q-PCR. We observed opposing effects at the different levels of Osx and HoxB4 expression. By day 14, collagen I level, calibrated with primary human osteoblasts, were increased in H9-EGFP-HoxB4(high) samples 17.2-fold (AE8.3 SEM, P ¼ 0.08 when compared to H9-EGFP), and a significant increase was found in H9-Osx-EGFP(low) cells of 10.5-fold (AE0.7 SEM, P < 0.05) (Fig. 3B) . This suggested that an abundant extracellular matrix could be formed from these cells. Therefore, we tested the expression of later osteogenic marker genes in these cells. The results indicated a possible trend that H9-Osx-EGFP(low) and H9-EGFP-HoxB4(high) possessed increased Bsp expression of 5-and 6.6-fold respectively (not significant), when calibrated to the undifferentiated H9 cells. Ocn levels were significantly ( P ¼ 0.03) up-regulated by 29.3-fold in H9-Osx-EGFP(low) cells, and by 21-fold in H9-EGFP-HoxB4(high) cells (Fig. 3C) .
Nodule formation and mineralization were analyzed using Alizarin Red S, which specifically gives a red stain in reaction with calcium salt crystals. We observed that by day 25 the Osx-transduced cells exhibited no evidence of enhanced extracellular calcium deposition compared to unmodified H9 cells (Fig. 3D) . However, high levels of HoxB4 expression resulted in an additive effect on mineral deposition, which correlated with enhanced collagen I synthesis.
Identification of proteins synthesized into the matrix revealed similar trends to the above described examination of mRNA levels. Bsp was detected at 70 kDa, and strong bands for collagen I ($180 kDa) were observed (Fig. 3E) .
Ectopic high levels of Osx expression in H9 cell line enhances differentiation towards hematopoietic-endothelial lineage
We next investigated the fate of cells expressing high levels of Osx and low levels of HoxB4, which were not able to produce any collagenous matrix. It has been speculated that a multipotent mesodermal progenitor population coexists in the osteogenic differentiation pool. Based on the morphological findings (see Fig. 3A) , we screened the Osx-transduced cells grown in differentiation medium for known hematopoieticendothelial markers.
HoxB4 transduced cells served as a control, due to their previously reported positive regulatory effect on CD34 induction (Sauvageau et al., 1995; Bowles et al., 2006) . In the medium supplemented with b-glycerophosphate, ascorbic acid phosphate and dexamethasone, the H9-EGFP transduced cells showed no effect on the increase of CD34 expression during 14 days of culture. HoxB4(low) cultures demonstrated an increase in CD34 expression of 1% by day 7, however by day 14, the number of CD34 expressing cells had increased to 4.3% (Fig. 4A, left part) .
It has been shown previously that the manipulation of cellular density affects hematopoietic differentiation (Slukvin et al., 2006) . At day 7, we split the cells, and compared the results to unsplit samples. The split control H9-EGFP population resulted in a significantly higher number of CD34 cells ( P < 0.0001) but the reduced cell density had a negative effect on the HoxB4 induced CD34þ population with a decrease to 2.5% in HoxB4-transduced cultures. On the other hand Osx(high) cells demonstrated a 1.8% increase by day 7, and 2.6% increase by day 14. Surprisingly the cultures that were split in half at day 7, resulted in an increase to 5.5% CD34þ cells. This difference in CD34 expression between the cells, subcultured at day 7 and those left in the original dish was significant ( P < 0.0001).
We performed similar tests on H9-Osx-EGFP(low) and H9-EGFP-HoxB4(high) expressing cells, and observed a significant ( P < 0.0001) decrease in CD34þ cell numbers in both cultures (Fig. 4A, right part) . These results correlated with our previous extracellular matrix formation results and confirmed that cells producing more extracellular matrix appeared to follow an osteogenic pathway.
Transcription factor HoxB4 is also a marker for hematopoiesis, and since HSC subpopulations with self-renewal capacity express HoxB4 (Sauvageau et al., 1994) we were interested if this factor was up-regulated by Osx induction. Q-PCR analysis with primers specifically detecting HoxB4 demonstrated an increase of 2.5-fold (AE0.9 SEM) relative to endogenous levels of K562 line in H9-Osx-EGFP(low) cells after 14 days maintained in the differentiation conditions, however this was not a significant increase. A significant up-regulation of HoxB4 ( P ¼ 0.0073) was on the other hand observed in H9-Osx-EGFP(high) cells (Fig. 4B) .
As for the confirmation, Gata1, another transcription factor, which is believed to be a key regulator of erythropoiesis and Fig. 3 . A: Light microscopy image of EGFP, Osx-EGFP and EGFP-HoxB4 expressing H9 cells after 1 week in osteogenic supplements. Osx expressing cells exhibited endothelial-like morphology, which was similar to HoxB4 expressing cells. Scale bar 100 mm. B,C: The formation of extracellular matrix by cells that had been treated with b-glycerophosphate, ascorbic acid phosphate and dexamethasone. Total RNA was harvested at various time-points, days 0, 7, and 14. Q-PCR analysis revealed that low Osx but high HoxB4 levels induced the expression of collagen I, mineral associated bone sialoprotein (Bsp), and osteocalcin (Ocn), a marker for late osteoblasts. D: Mineral formation was examined by Alizarin Red S staining. The deposition of calcium salts was observed in bone-like nodules in the osteogenic cultures at day 25. Photographs of the whole well were taken and cropped to equal sizes using Adobe Photoshop. E: Western blot analysis for bone-related marker proteins. Bsp was detected at 70 kDa, and strong bands for collagen I were observed around 180 kDa. Human osteosarcoma line Saos-2 was included as a positive control. Fig. 4 . EctopichighlevelsofOsx expressioninpluripotentcellsincreasedthedifferentiationtowardsthe hematopoietic-endotheliallineage.A:Cells were grown for 14 days with osteogenic medium. At day 7, some of the cultures were split at a 1:2 ratio and continued until day 14. H9-EGFPHoxB4(low) cells demonstrated an increase in CD34 expression of 4.3% at day 14, which decreased to 2.5% in split cultures. H9-Osx-EGFP(high) had a 2.63% increase in CD34R cells by day 14, and after splitting the amount of positive cells was 5.5%. In H9-EGFP-HoxB4(high) and H9-Osx-EGFP(low) cells a significant reduction in the number of CD34R cells was observed after 7 days in culture. B: HoxB4 expression increased $2.5-fold in H9-Osx-EGFP(low) cells after 14 days in the differentiation conditions. C: Gata1 expression was up-regulated $40-fold in H9-EGFP-HoxB4(low) (upper part), and a $230-fold increase was observed in H9-Osx-EGFP(high) at day 14 grown in monolayers under osteogenic conditions (lower part).
whose expression is restricted to the hematopoietic system (for review see Kobayashi and Yamamoto, 2007) was included in the study as a relatively late hematopoietic marker compared to HoxB4 and CD34. First we tested if ectopic expression of HoxB4 was able to increase Gata1 transcription. At day 14, a 40-fold increase in H9-EGFP-HoxB4(low) expressing populations was detected, but only an 8-fold increase was found in H9-EGFP-HoxB4(high) expressing populations when compared to undifferentiated H9-EGFP. In Osx-transduced cells, we observed a 23-fold higher Gata1 levels already in undifferentiated populations of H9-Osx-EGFP(high), which increased by 10-fold after 2 weeks in culture with b-glycerophosphate, ascorbic acid phosphate and dexamethasone. This increase was significantly higher compared to the samples of H9-Osx-EGFP(low) and H9-EGFP-HoxB4(low) at the given time-point (Fig. 4C ).
Discussion
Transgene silencing is known to occur during differentiation of HESCs, therefore we used lentiviral vectors which have previously been reported to be less affected by gene silencing during HESC differentiation (Pfeifer et al., 2002; Ma et al., 2003) . Stable transgene expression is dependent on the promoter and the effects can be inconsistent between different cell types. Here, we used a system based on the ubiquitin promoter in lentivectors (Imreh et al., 2004; Unger et al., 2008) . As we aimed to study the ectopic expression of transcription factors in undifferentiated stem cells, we used a selectable lentiviral backbone in order to prevent multiple integration to lower the risk of insertional mutagenesis, and also to reduce the risk of obtaining too high levels of expression, which has previously been shown to reduce final maturation in stem cells (Schiedlmeier et al., 2003) .
The transcription factor Osx has been identified as a crucial regulator of osteogenesis and is predominantly expressed by early osteoblastic cells (Nakashima et al., 2002) . To our knowledge, there are so far only two studies presenting the ectopic expression of Osx in pluripotent cells. Tai et al. (2004) reported a study using mouse ESCs, where they examined the differentiation of the cells following embryoid body induction. We have previously found that embryoid body formation is not needed for osteogenesis in HESCs (Karner et al., 2007) , but acknowledge that this stage might influence the differentiation pattern of pluripotent cells and thus needs further investigation. In a second study, the same authors used the HESC line, H1 (Tai et al., 2005 ) cultured on mouse fibroblasts and thus the cells could be qualitatively different from ours. Furthermore, this study did not focus on the analysis of osteogenesis.
Our finding, demonstrating two levels of expressions was probably due to the random integration of lentiviral vectors. The Osx-transduced undifferentiated cells showed reduced expressed levels of markers generally associated with the undifferentiated state during prolonged cultivation in vitro, however the proliferative status was not significantly impaired. Expression of Nanog, an early pluripotency supporting transcription factor, was significantly reduced in undifferentiated HESCs expressing high levels of Osx. The question remains as to whether such high Osx levels inhibited the differentiation or supported Nanog expression, particularly when $26% of the cells still expressed Nanog after 1 week. Nanog is believed to collaborate with other transcription factors to specify a pluripotent state and thus form the basis of a transcription factor hierarchy (for review see Boyer et al., 2006) , and it has also been demonstrated to directly block differentiation (Boyer et al., 2005) . However, it is likely that also other genetic, epigenetic and environmental factors play an important role in this process. Moreover, it is known that tissue-specific transcription factors, like Osx and HoxB4 studied here, regulate tissue restricted gene expression through the interaction with transcriptional co-activators, chromatin remodeling complexes, and basal transcriptional machinery (Lemon and Tjian, 2000) . For example, Osx has been shown to interact with Brg-1, which is a catalytic component of SWI/SNF chromatin remodeling complex which regulate tissue-specific gene expression (Hatta et al., 2006) . A similar finding has been described for HoxB4, which also needs co-factors to be able to reorganize the local chromatin environment (Gilthorpe et al., 2002) .
The expression of Osx at low levels induced the transcription of HoxB4. This supports the notion of cell-cell interactions between early pre-osteoblasts and HSCs on the BM endosteal surface, required for hematopoiesis (Gong, 1978) . Furthermore, the up-regulated levels of mineralization-associated gene mRNAs, such as collagen I, Bsp and Ocn, by high HoxB4 could also indicate a role for HoxB4 during pathological mineralization perhaps similar to that found in blood vessels. To elucidate this we also performed gene expression analysis with human cord blood endothelial cells and adult CD34 cells, which revealed that these cells possessed high endogenous levels of HoxB4, thereby supporting the speculation that Bsp has a role in ectopic mineral formation (Ganss et al., 1999; Tyson et al., 2003) .
In comparison, Osx expression at high levels induced the up-regulation of CD34 in vitro, which is a common marker for human hemato-endothelial progenitor cells, and is selectively expressed on some downstream human hematopoietic cells (Gangenahalli et al., 2006) . Furthermore, it also induced the up-regulation of Gata1, a late marker for the erythroid pathway. We conclude that both Osx and HoxB4 possibly coordinate each other during early blood and bone cell differentiation, and the suggested mechanism could be based on potentially removing co-factors from each other.
Early studies by Taichman and Emerson (1998) demonstrated that cells involved in bone formation possessed stem cell supporting activity, and that both mouse and human osteoblastic cell lines secreted a great number of cytokines that promoted the proliferation of hematopoietic cells in in vitro culture. Here, we show that low levels of Osx expressed in modified H9 cells had similar levels to those found in human osteoblasts, and which indeed can contribute to enhanced osteogenesis, based on the detection of up-regulated collagen I and Ocn levels. Therefore, since osteoblasts have the capacity to produce a vast array of cytokines, which are important for several hematopoietic pathways, this may promote the differentiation of Osx-low expressing cells towards CD34þ populations.
We conclude that for an enhanced osteogenesis originating from in vitro cultured HESCs, the correct levels of ectopic transcription factors need to be established. Our data also highlight the notion of a close relationship between early blood and bone development.
